Taho Pharmaceuticals Company Description

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan.

Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia.

The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid and TAH9901 Methylphenidate patch for ADHD treatment.

Taho Pharmaceuticals Ltd. was founded in 2010 and is based in Taipei, Taiwan.